MARKET

AURA

AURA

Aura Biosciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.27
-0.17
-1.37%
Opening 12:24 06/29 EDT
OPEN
12.50
PREV CLOSE
12.44
HIGH
12.52
LOW
12.02
VOLUME
30.89K
TURNOVER
231.80K
52 WEEK HIGH
26.16
52 WEEK LOW
11.98
MARKET CAP
359.02M
P/E (TTM)
-7.6640
1D
5D
1M
3M
1Y
5Y
Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer
Benzinga · 6d ago
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care Aura Biosciences Inc.
Benzinga · 6d ago
BRIEF-Aura Biosciences Reports Topline Data From A Study Of Belzupacap Sarotalocan (Au-011) VS Plaque Radiotherapy Supporting
BRIEF-Aura Biosciences Reports Topline Data From A Study Of Belzupacap Sarotalocan (Au-011) VS Plaque Radiotherapy Supporting
Reuters · 6d ago
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/21 13:03
BRIEF-Aura Biosciences To Present Updated Belzupacap Sarotalocan Data On Multiple Studies
reuters.com · 06/17 11:47
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
CAMBRIDGE, Mass., June 17, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of...
Business Wire · 06/17 11:00
Bullish Aura Biosciences, Inc. (NASDAQ:AURA) investors are yet to receive a pay off on their US$716k bet
The recent 15% drop in Aura Biosciences, Inc.'s ( NASDAQ:AURA ) stock could come as a blow to insiders who purchased...
Simply Wall St. · 06/17 10:40
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
CAMBRIDGE, Mass., May 26, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclin...
Business Wire · 05/26 21:26
More
No Data
Learn about the latest financial forecast of AURA. Analyze the recent business situations of Aura Biosciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AURA stock price target is 32.33 with a high estimate of 38.00 and a low estimate of 29.00.
High38.00
Average32.33
Low29.00
Current 12.27
EPS
Actual
Estimate
-2.01-1.51-1.00-0.50
Q4 2020
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 34
Institutional Holdings: 13.75M
% Owned: 47.00%
Shares Outstanding: 29.26M
TypeInstitutionsShares
Increased
14
360.91K
New
5
333.98K
Decreased
8
11.44K
Sold Out
3
14.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.19%
Pharmaceuticals & Medical Research
+0.59%
Key Executives
Non-Executive Chairman/Independent Director
David Johnson
Chief Executive Officer/Director
Elisabet de los Pinos
Chief Financial Officer/Primary Contact
Julie Feder
Chief Operating Officer
Mark De Rosch
Other
Christopher Primiano
Other
Cadmus Rich
Independent Director
Giovanni Mariggi
Independent Director
Antony Mattessich
Independent Director
Rajesh Parekh
Independent Director
Sapna Srivastava
Independent Director
Karan Takhar
No Data
No Data
About AURA
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing virus-like drug conjugates (VDCs), a novel class of therapies for the treatment of multiple oncology indications. The Company’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 consists of human papilloma virus (HPV)-derived VLP conjugated to hundreds of infrared laser-activated molecules. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is in development for ocular cancers, with an ongoing Phase II dose escalation clinical trial evaluating first-line treatment of choroidal melanoma. It seeks to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer.

Webull offers kinds of Aura Biosciences Inc stock information, including NASDAQ:AURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AURA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AURA stock methods without spending real money on the virtual paper trading platform.